Traders should monitor the upcoming NEO100 interim data readout (~August 2026) and FDA feedback on NEO212 as key value inflection points; however, continued high G&A spend and lack of near-term revenue may pressure valuation absent transformative data.
Price Chart
Executive Summary
NeOnc Technologies reported Q4 2025 earnings with a widened net loss of $62.1M, driven by higher G&A and R&D expenses, while highlighting clinical progress in its NEO212 and NEO100 programs and securing a $10M PIPE anchor investment. Despite promising early data in CNS cancer trials, the significant year-over-year increase in losses and lack of revenue weighs on fundamentals. Near-term catalysts include an FDA meeting and Phase 2a data readout expected in August 2026.
Key Financial Metrics
Key Facts
- Net loss of $62.1M in Q4 2025 vs. $11.9M in Q4 2024; EPS loss of $3.20 vs. $0.69
- G&A expenses rose to $4.8M from $1.7M; R&D increased to $3.6M from $3.0M YoY
- No revenue generated; company remains in clinical development phase
- NEO212 Phase 1 completed with RP2D set at 610 mg; planning Type B FDA meeting
- NEO100 Phase 2a trial fully enrolled; interim data expected ~August 2026
- Reported 24% radiographic remission rate and 44% six-month PFS in updated data
- Secured $10M PIPE anchor commitment from Cinctive Capital
- Appointed new CEO, CAO, and expanded Scientific Advisory Board
Financial Impact
Increased cash burn with $62.1M net loss in Q4, partially offset by $10M PIPE financing; no revenue generation
Risk Factors
- High cash burn rate with no revenue; future dilution likely
- Clinical trial results are early-stage and may not translate to pivotal success
- Forward-looking statements dominate narrative; actual data remain limited
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $2.95 | awaiting T+60 | — | $2.82 (−4.41%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $2.82 (+4.44%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $2.82 (−15.32%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $2.82 (−17.30%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $2.82 (−5.69%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $2.82 (+22.95%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $2.82 (+22.95%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $2.82 (−39.68%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $2.82 (−49.01%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $2.82 (−18.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers